Candida Antigen and Bivalent HPV Vaccine in the Treatment of Multiple Warts
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age9+
SponsorZagazig University
About this trial
To follow up the efficacy and safety of Candida antigen, bivalent HPV vaccine in treatment of common warts either mono or combined intralesional therapy
Eligibility criteria
Qualifiers
patients with multiple, recalcitrant, or non-recalcitrant common warts of different sites, sizes, duration, and with or without distant lesions will be enrolled in the study
Disqualifiers
Pregnant female. Hypersensitivity to Candida antigen or bivalent HPV vaccine
Trial design
Treatments tested in this trial
- Candida antigen vaccine
- Bivalent HPV vaccine
Treatment groups
162 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov